Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration

Table 6

Characteristics of study populations at baseline.

		Pegaptanib^1 0.3 mg (𝑛=295)	Pegaptanib^1 UC (𝑛=296)	Ranibizumab^2 (𝑛=379)	Ranibizumab^2 UC (𝑛=381)
Sex, no(%)
Male		133 (45)	120 (40)	163 (43)	143 (38)
Female		164 (55)	178 (60)	217 (57)	238 (62)
Race, no(%)
White		283 (96)	284 (95)	268 (97)	371 (97)
Other		12 (4)	14 (5)	12 (3)	10 (3)
Age, no(%)
50–64		19 (6)	21 (7)	30 (8)	19 (5)
65–74		86 (29)	94 (32)	104 (27)	102 (27)
75–84		155 (53)	160 (54)	188 (50)	206 (54)
≥85		35 (12)	23 (8)	57 (15)	54 (14)
Mean				76.6	77.3
Range				52–93	53–95
LC, no(%)
PC		72 (24)	76 (26)	135 (36)	141 (37)
MC		111 (38)	102 (34)	96 (25)	89 (23)
OC		112 (38)	120 (40)	149 (39)	151 (40)
Mean LS		3.7	4.2	3.5	3.5
ETDRS VA	Mean	56.2	52.7	51.3	50.6
	≤20/200	45 (15)	45 (15)	63 (17)	78 (20)
	20/40>VA>20/200	222 (76)	221 (75)	274 (72)	267 (71)
	≥20/40	27 (9)	30 (10)	42 (11)	39 (9)

¹From VISION Study [6] of pegaptanib, and safety and efficacy summaries provided by Pfizer Inc.
²Pooled estimates from MARINA and ANCHOR [7, 8] studies of ranibizumab.
UC: usual care; LC: lesion composition; PC: predominantly classic; MC: minimally classic; OC: occult with no classic; LS: lesion size; ETDRS VA: early Treatment of Diabetic Retinopathy Study visual acuity.